Acasti Pharma (NASDAQ:ACST) Stock Price Passes Above 200 Day Moving Average of $2.74

Acasti Pharma Inc. (NASDAQ:ACST) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.74 and traded as high as $2.93. Acasti Pharma shares last traded at $2.93, with a volume of 2,465 shares.

Analyst Upgrades and Downgrades

Separately, Craig Hallum began coverage on shares of Acasti Pharma in a report on Wednesday, February 7th. They set a “buy” rating and a $6.00 price target for the company.

Acasti Pharma Stock Performance

The firm has a market cap of $27.53 million, a PE ratio of -0.58 and a beta of 1.49. The firm’s 50-day moving average price is $3.33 and its two-hundred day moving average price is $2.74.

Acasti Pharma (NASDAQ:ACST) last issued its quarterly earnings data on Monday, February 12th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.02. As a group, sell-side analysts predict that Acasti Pharma Inc. will post -1.44 earnings per share for the current fiscal year.

Acasti Pharma Company Profile

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.